ReviR Therapeutics Appoints Paul August, Ph.D., as Chief Scientific Officer

SOUTH SAN FRANCISCO, Calif., July 1, 2022 /PRNewswire/ -- ReviR Therapeutics, a biotechnology company focused on developing RNA-targeting small molecule drugs, announced the appointment of Paul August, Ph.D., as the Chief Scientific Officer. "We are thrilled to welcome Dr. August to our...

Click to view original post